Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | GLB1 | P16278 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20331193 | 0.94 | S1PR1 (0.50) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL19404534 | 0.92 | S1PR1 (0.53) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL28345048 | 0.92 | S1PR1 (0.53) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL14131261 | 0.88 | S1PR1 (0.41) | S1PR1S1PR3S1PR5S1PR4OPRM1 | |
| SCHEMBL16263876 | 0.87 | S1PR1 (0.47) | S1PR1S1PR3S1PR5S1PR4DRD2 | |
| SCHEMBL6890281 | 0.87 | S1PR4 (0.35) | S1PR1S1PR3S1PR5S1PR4OPRM1 | |
| SCHEMBL16508917 | 0.82 | NOS3 (0.40) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL26774329 | 0.82 | S1PR1 (0.46) | S1PR1S1PR3S1PR5S1PR4OPRM1 | |
| SCHEMBL14921181 | 0.81 | HRH3 (0.35) | S1PR1S1PR3S1PR5S1PR4OPRM1 | |
| SCHEMBL23074854 | 0.80 | GBA1 (0.37) | S1PR1S1PR3S1PR5S1PR4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116866-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 杭州多域生物技术有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | S1PR1 3618/4885S1PR3 2823/4885S1PR5 2447/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | S1PR1 2180/4885S1PR3 2750/4885S1PR5 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.